Opko Diabetes possibility?

It's not in the news. It is simply a link to a bot-type summary of outdated, irrelevant information. I'd be surprised if we hear anything from LeaderMed this year, or even within the time frame in which the diabetes/obesity drug market remains fertile. It's Opko. And that means black hole. On another topic, two and a half years ago, during the Wainwright fireside chat, Rubin mentioned that there would be milestones coming from Camp4  'over the next year' for the AntagoNAT technology. 

About $2 million in salary later, Mr. Rubin has still not delivered on that promise. So I expect nothing from him, or his boss, regarding Oxyntomodulin, either from LeaderMed or ENTX.